Novel tyrosine kinase inhibitors in chronic myelogenous leukemia

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


PURPOSE OF REVIEW: The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia. RECENT FINDINGS: Imatinib therapy has significantly improved prognosis of chronic myeloid leukemia. A minority of patients with chronic-phase disease (4% annually) and considerably more in advanced stages develop resistance. This is attributed, in 40-50% of cases, to the development of BCR-ABL (breakpoint cluster region/Abelson oncogene) tyrosine kinase domain mutations that impair imatinib binding. This has led to the development of more potent novel tyrosine kinase inhibitors that can overcome both BCR-ABL-dependent and BCR-ABL-independent mechanisms of resistance. Preliminary results of phase I and II trials with dasatinib and nilotinib have provided promising data that may reduce disease progression and potentially prevent acquired resistance to the tyrosine kinase inhibitors. SUMMARY: Novel tyrosine kinase inhibitors with more potent and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinases are promising and may further improve prognosis in chronic myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)578-583
Number of pages6
JournalCurrent Opinion in Oncology
Issue number6
StatePublished - Nov 2006
Externally publishedYes


  • Chronic myeloid leukemia
  • Imatinib
  • Mutations
  • Novel tyrosine kinase inhibitors
  • Resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel tyrosine kinase inhibitors in chronic myelogenous leukemia'. Together they form a unique fingerprint.

Cite this